SK12812002A3 - Spôsob liečenia psoriázy - Google Patents

Spôsob liečenia psoriázy Download PDF

Info

Publication number
SK12812002A3
SK12812002A3 SK1281-2002A SK12812002A SK12812002A3 SK 12812002 A3 SK12812002 A3 SK 12812002A3 SK 12812002 A SK12812002 A SK 12812002A SK 12812002 A3 SK12812002 A3 SK 12812002A3
Authority
SK
Slovakia
Prior art keywords
psoriasis
inhibitor
tomoxetine
epinephrine
acid
Prior art date
Application number
SK1281-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Holly Read Thomasson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SK12812002A3 publication Critical patent/SK12812002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1281-2002A 2000-03-07 2001-02-20 Spôsob liečenia psoriázy SK12812002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18750800P 2000-03-07 2000-03-07
PCT/US2001/005260 WO2001066101A2 (en) 2000-03-07 2001-02-20 Treatment of psoriasis

Publications (1)

Publication Number Publication Date
SK12812002A3 true SK12812002A3 (sk) 2003-08-05

Family

ID=22689272

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1281-2002A SK12812002A3 (sk) 2000-03-07 2001-02-20 Spôsob liečenia psoriázy

Country Status (19)

Country Link
US (1) US6683114B2 (hu)
EP (1) EP1267859A2 (hu)
JP (1) JP2003525899A (hu)
KR (1) KR20020081403A (hu)
CN (1) CN1407890A (hu)
AU (1) AU4529101A (hu)
BR (1) BR0108980A (hu)
CA (1) CA2400571A1 (hu)
DZ (1) DZ3282A1 (hu)
EA (1) EA200200948A1 (hu)
HR (1) HRP20020729A2 (hu)
HU (1) HUP0204551A2 (hu)
IL (1) IL150479A0 (hu)
MX (1) MXPA02008659A (hu)
NO (1) NO20024236D0 (hu)
PL (1) PL357042A1 (hu)
SK (1) SK12812002A3 (hu)
WO (1) WO2001066101A2 (hu)
ZA (1) ZA200205266B (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
CN2559015Y (zh) * 2002-04-29 2003-07-02 谢基生 电动式双层近红外滤光型防盗摄影监控装置
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004075902A1 (en) * 2003-02-28 2004-09-10 Amedis Pharmaceuticals Ltd. Use of silicon derivatives of venlafaxine for the treatment or prevention of psoriasis or panic disorder
WO2005011583A2 (en) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Treatment of allergic rhinitis and asthma
WO2007146796A2 (en) * 2006-06-13 2007-12-21 Ramot At Tel-Aviv University Ltd. Antiproliferative compounds, compositions and methods of use
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US9326935B2 (en) * 2013-11-08 2016-05-03 Eli Lilly And Company Atomoxetine solution

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU183323B (en) * 1981-02-11 1984-04-28 Richter Gedeon Vegyeszet Process for producing 17,18-dihydro-apovincaminol-3-comma down comma aaove-4-comma down comma above-5-comma down comma aaove-trimethoxy-benzoate and acid additional salts thereof
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US6150396A (en) * 1997-03-07 2000-11-21 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
ZA985765B (en) * 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
EP1069900B1 (en) * 1998-04-09 2005-08-10 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of neuropsychiatric disorders
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6403645B2 (en) * 2000-03-16 2002-06-11 President And Fellows Of Harvard College Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them

Also Published As

Publication number Publication date
WO2001066101A2 (en) 2001-09-13
MXPA02008659A (es) 2003-02-24
WO2001066101A3 (en) 2002-02-07
NO20024236L (no) 2002-09-05
HRP20020729A2 (en) 2004-02-29
EA200200948A1 (ru) 2003-02-27
US20030045585A1 (en) 2003-03-06
BR0108980A (pt) 2003-06-03
DZ3282A1 (fr) 2001-09-13
HUP0204551A2 (hu) 2003-06-28
JP2003525899A (ja) 2003-09-02
CA2400571A1 (en) 2001-09-13
AU4529101A (en) 2001-09-17
PL357042A1 (en) 2004-07-12
US6683114B2 (en) 2004-01-27
ZA200205266B (en) 2003-10-01
EP1267859A2 (en) 2003-01-02
CN1407890A (zh) 2003-04-02
NO20024236D0 (no) 2002-09-05
IL150479A0 (en) 2002-12-01
KR20020081403A (ko) 2002-10-26

Similar Documents

Publication Publication Date Title
CA2304657C (en) Treatment of conduct disorder
AU740109B2 (en) Treatment of oppositional defiant disorder
CZ2001677A3 (cs) Farmaceutický prostředek
CA2332253A1 (en) Combination therapy for treatment of depression
JP2006509751A (ja) β−３アドレナリン受容体アゴニストとセロトニン及び／又はノルエピネフリン再取り込み阻害剤とを含む医薬組成物
HUT71222A (en) Pharmaceutical compositions for inhibiting pulmonary hypertenzive diseases containing 2-phenyl-3-aroyl-benzotiophene derivatives and process for their preparation
SK12812002A3 (sk) Spôsob liečenia psoriázy
PT659411E (pt) Metodo para aumentar a libido em mulheres pos-menopausicas
EP0759299A1 (en) Potentiation of serotonin response
EP1383495A1 (en) Duloxetine for treatment of hot flashes
CA2593854A1 (en) Organic compounds
JPH11506787A (ja) カルシウムチャンネルの調節
CZ20031339A3 (cs) Léčení úzkostných poruch
US20050228052A1 (en) Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine
US20040152733A1 (en) Duloxetine for treatment of hot flashes
EA010868B1 (ru) Применение производных бицикло[2.2.1]гептана для приготовления нейропротекторных фармацевтических композиций
WO2005023265A1 (en) Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
US5733937A (en) Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
US20040034106A1 (en) Treatment of anxiety disorders
MXPA00002829A (en) Treatment of conduct disorder
ZA200303738B (en) Treatment of anxiety disorders.